SPRO — Spero Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1701108 ·
Last close
$2.86
Market Cap
$165.60M
52W High
$2.94
52W Low
$2.11
ADV30
555,232
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 258,000 | — | -7,538,000 | -7,203,000 | 59,021,000 | 56,129,000 | 6,087,000 |
| Dec 2025 | 39,658,000 | — | 31,405,000 | 31,520,000 | 68,919,000 | 40,265,000 | 9,898,000 |
| Sep 2025 | 3,048,000 | — | -7,329,000 | -7,382,000 | 54,170,000 | 48,616,000 | 27,676,000 |
| Jun 2025 | 11,802,000 | — | -2,361,000 | -1,700,000 | 62,119,000 | 31,194,000 | 29,291,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,624,000
Investing CF
—
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-451,066,000
Inventory
—
Receivables
$25,387,000
ST Investments
—
EBIT TTM
$7,159,000
Pretax Income TTM
$8,833,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,186,000
EBITDA
—
Free Cash Flow
$13,691,625
Enterprise Value
$106,153,120
Total Cash
$56,129,000
Total Debt
$2,474,000
Shares Out
57,901,493
Trailing EPS
$0.27
Book Value
$1.05
ROE
35.1%
ROA
13.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,619,000 | 7,159,000 | 8,572,000 | 68,919,000 | 9,898,000 | — | -12,624,000 |
| Dec 2024 | 27,396,000 | -72,484,000 | -68,566,000 | 110,543,000 | 64,420,000 | — | -23,444,000 |
| Dec 2023 | 96,735,000 | 26,787,000 | 22,806,000 | 182,390,000 | 75,496,000 | — | -32,995,000 |
| Dec 2022 | 48,579,000 | -30,567,000 | -46,415,000 | 124,802,000 | 48,868,000 | — | -7,731,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.11
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V. | $165.42M | $1.57 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $165.34M | $4.04 | — |
| ENLV | Enlivex Ltd. | $164.88M | $0.68 | — |
| OKUR | OnKure Therapeutics, Inc. | $166.43M | $4.12 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $167.19M | $0.88 | — |
News headlines (Yahoo Finance, 1h cache)
Promising Penny Stocks To Consider In May 2026
2026-05-15 12:05 · Yahoo
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
2026-05-13 20:05 · Yahoo
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
2026-04-22 22:03 · Yahoo
Uncovering 3 Penny Stocks With Market Caps Under $700M
2026-04-08 18:05 · Yahoo
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
2026-03-26 20:05 · Yahoo
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
2026-03-18 20:05 · Yahoo
Airgain And 2 Other Promising Penny Stocks
2026-02-05 18:06 · Yahoo
3 Promising Penny Stocks With Market Caps Up To $300M
2026-01-07 18:05 · Yahoo
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
2025-12-19 13:00 · Yahoo
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
2025-12-15 10:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.